Evidence map›Paper›PMID 38136302›Full record

ArticleCancers2023

Utilising Pancreatic Exocrine Insufficiency in the Detection of Resectable Pancreatic Ductal Adenocarcinoma.

Declan McDonnell, Paul R Afolabi, Sam Wilding, Gareth O Griffiths, Jonathan R Swann, Christopher D Byrne, Zaed Z Hamady

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Declan McDonnellHuman Development & Health, University of Southampton, Southampton SO16 6YD, UK.ORCID 0000-0001-9088-9875
Paul R AfolabiHuman Development & Health, University of Southampton, Southampton SO16 6YD, UK.
Sam WildingCancer Research UK Southampton Clinical Trials Unit, University of Southampton, Southampton SO17 1BJ, UK.
Gareth O GriffithsUniversity Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK.
Jonathan R SwannHuman Development & Health, University of Southampton, Southampton SO16 6YD, UK.
Christopher D ByrneHuman Development & Health, University of Southampton, Southampton SO16 6YD, UK.ORCID 0000-0001-6322-7753
Zaed Z HamadyHuman Development & Health, University of Southampton, Southampton SO16 6YD, UK.ORCID 0000-0002-4591-5226
University Hospital Southampton NHS Foundation Trust · GBCancer Research UK · GBUniversity of Southampton · GB

Funding

Cancer Research UK 25352Cancer Research UK C45617/A29908
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is usually diagnosed late, leading to a high mortality rate. Early detection facilitates better treatment options. The aim of this UK-based case-control study was to determine whether two validated tests for pancreatic exocrine insufficiency (PEI), namely, the

Indexed as

13CadenocarcinomaelastaseexocrineinsufficiencypancreaticPDACPEItriglyceride

Identifiers

PMID38136302
PMCPMC10741412
OpenAlexW4389480600

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.